US-based drug distributor AmerisourceBergen has signed a definitive agreement to acquire PharMEDium Healthcare Holdings, a compounded sterile preparations (CSPs) provider, from Clayton, Dubilier & Rice for $2.575bn.
According to the company, the acquisition is expected to generate around $30m in synergies by fiscal 2018.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PharMEDium is a provider of customised outsourced CSPs that meet specific hospital and physician clinical needs and quality standards in formulations that are not otherwise commercially available.
AmerisourceBergen president and CEO Steven Collis said: "The acquisition of PharMEDium strengthens our core business and meaningfully expands our innovative service offerings for health systems.
"PharMEDium is a compelling addition to our business, which allows us to provide differentiated offerings and further increases our ability to drive both value and efficiency for our health systems customers in a way that enhances patient safety and helps improve patient outcomes."
The acquisition will allow AmerisourceBergen to strengthen its business of supplying compounded drugs to hospitals.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPharMEDium CEO William Spalding said: "We are excited about this transaction, which brings together two great brands built on the same strong foundation of patient safety and quality, service excellence and value to our customers."
Following completion of the transaction, which is expected in the first quarter of fiscal 2016, PharMEDium will become a part of AmerisourceBergen Drug Corporation.
The transaction is subject to regulatory review and other customary closing conditions.
The sterile-to-sterile CSPs of PharMEDium are prepared in FDA and state board of pharmacy inspected facilities, using FDA-approved or allowed drugs in finished dosage form and FDA-approved diluents and containers.
These CSPs are in a ready to use form with improved safety, labelling, sterility assurance, and extended expiration dating supported by appropriate studies that often exceeds what hospital pharmacies can accomplish on their own.
PharMEDium maintains four compounding facilities, provides a broad range of 2,000 SKUs and serves more than 3,000 hospital customers across all 50 states.
